Tagged with Gilead

Sweden The top 50 most sold drugs in Sweden for 2018. AbbVie’s Humira takes the top spot for the second year running, followed by Gilead’s Epclusa and BMS and Pfizer’s Eliquis.   Made with Visme Infographic Maker  

China Rogers Luo Yongqing, global VP and general manager (China), Gilead Sciences, shares the key accomplishments of Gilead in China with six innovative products approved in just 15 months; the strategic significance of Gilead China as the newest affiliate for Gilead globally; and their commitment to maximizing patient access in China…

Egypt Egypt has found a way to profit from the country’s access to cheap Hep C drugs by offering package holidays to tourists suffering from the disease, but the ‘tour and cure’ model raises numerous questions.   Egypt has a long history struggling with Hepatitis C (HCV) that started in the…

UK Recently appointed as general manager & vice president of Gilead’s UK and Ireland operations, Hilary Hutton-Squire highlights the uniqueness of the UK’s healthcare system, its expertise in life sciences and global leadership in clinical trials. To her, the UK has to maintain its core differentiators, such as a health technology…

Pharma The top 10 pharmaceutical companies in Canada for 2016 in terms of total sales and market share. Johnson & Johnson leads the way with USD 2.93 billion in sales, followed by Novartis with USD 1.24 billion and TEVA with USD 1.19 billion.

Canada Kennet Brysting, General Manager of Gilead Sciences Canada, Inc. outlines the strategic significance of the Canadian affiliate to Gilead Sciences globally, including its manufacturing and R&D footprint, the challenge of managing the financial costs of breakthrough therapies, and Gilead’s success in advancing innovative therapies in the fields of HIV and…

Austria Austria has long been merely a cog in the wheel of global R&D, lying in the shadows of neighboring research giants, Germany and Switzerland. Now, however, this perception is changing as Austria capitalizes on its ideal central European location and impressively educated workforce. “From a biotech perspective, [Austria] has a…

Austria Clemens Schödl, general manager of Gilead Austria, discusses Gilead’s footprint and reputation in Austria as the leading global player in HIV treatment and what must be done to bring Austrian innovation into a new era to fully leverage Gilead’s life changing treatments. As general manager, could you introduce our international…

Pharma André Lüscher of Gilead Switzerland, reveals how the case of Sovaldi demonstrates the challenges for a healthcare system to handle a truly disruptive medical innovation, the knock-on effect on Gilead´s business model, and ensuring that those affected with hepatitis C are able to receive treatment in Switzerland. A lot has…

Pharma The following chart shows the leading innovators in Italian pharmaceuticals. Gilead leads the way with 135% growth, all of which comes from the hospitals sector. Click here to read more articles and interviews from Italy, and to download the latest free pharma report on the country.

Pharma The CEO of CzechInvest elaborates on the significance of the healthcare and life science industry for the Czech Republic’s transition into an industry 4.0. Furthermore, he reviews what the Czech Republic has to offer for foreign investors over its regional neighbors. Before assuming the position of CEO at CzechInvest you…

Pharma Former Egyptian Minister of Health Adel Adawy discusses the reforms needed in the Egyptian healthcare system and the progress made in the fight against HCV over the last two years. What structural changes need to be made in the Egyptian healthcare system? First of all, Egypt needs to have three…